Core Viewpoint - The stock of Gossamer Bio, Inc. (01167) has seen a significant increase, rising over 6% during trading, attributed to positive developments in the company's financial and clinical research activities [1] Financial Developments - Gossamer Bio's subsidiary, Beijing Gossamer, has received an initial payment of RMB 125 million from Haisong Capital, enhancing the group's cash reserves [1] - The receipt of this payment is expected to support the advancement of the company's innovative oncology therapy pipeline [1] Clinical Research Achievements - Gossamer Bio announced that the clinical I/IIa study results of its self-developed KRAS G12C inhibitor, Glecirasib, in combination with the SHP2 inhibitor, JAB-3312, have been published in the prestigious medical journal, The Lancet Respiratory Medicine [1] - This publication marks the first time systematic clinical data on the combination of KRAS G12C and SHP2 oral small molecule therapies has appeared in such a high-impact journal [1]
港股异动 | 加科思-B(01167)盘中涨超6% 附属收到1.25亿元首付款 联合疗法登上《柳叶刀》